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Abstract
Background
Resistance to isoniazid is the most common form of drug-resistance in tuberculosis. How-
ever only a tiny proportion of TB patients in the world have access to isoniazid drug suscepti-
bility testing—the widely implemented Xpert MTB/RIF technology only tests for resistance
to rifampicin. Patients with isoniazid mono resistance that is not identified at baseline are
treated with a standard regimen that effectively results in rifampicin mono-therapy during
the latter four months of the six month treatment course, exposing remaining viable organ-
isms to a single agent and greatly increasing the risk of development of multi drug-resistant
TB. Unusually, Peru has pioneered universal pre-treatment drug susceptibility testing with
methods that identify isoniazid resistance and has thus identified a large number of individu-
als requiring tailored therapy. Since 2010, treatment in Peru for isoniazid-resistant tubercu-
losis without multidrug-resistant tuberculosis (Hr-TB) has been with a standardized nine-
month regimen of levofloxacin, rifampicin, ethambutol and pyrazinamide. The objectives of
this study were to evaluate the outcomes of treatment for patients with Hr-TB initiating treat-
ment with this regimen between January 2012 and December 2014 and to determine factors
affecting these outcomes.
Methods
Retrospective cross-sectional study; case data were obtained from the national registry of
drug-resistant tuberculosis. Patients diagnosed with isoniazid resistant TB without resis-
tance to rifampicin, pyrazinamide, ethambutol and quinolones as determined by either a
rapid drug susceptibility testing (DST) (nitrate reductase test, MODS, Genotype
MTBDRplus) or by the proportion method were included.
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Findings
A total of 947 cases were evaluated (a further 403 without treatment end date were
excluded), with treatment success in 77.2% (731 cases), loss to follow-up in 19.7% (186
cases), treatment failure in 1.2% (12 cases), and death in 1.9% (18 cases). Unfavorable out-
comes were associated in multivariate analysis with male gender (OR 0.50, 95% CI 0.34–
0.72, p<0.05), lack of rapid DST (OR 0.67, 95% CI 0.50–0.91, p = 0.01), additional use of an
injectable second-line anti-tuberculous drug (OR 0.46, 95% CI 0.31–0.70, p<0.05), and
treatment initiation in 2014 (OR 0.77, 95% CI 0.62–0.94, p = 0.01).
Interpretation
The treatment regimen implemented in Peru for isoniazid resistant TB is effective for TB
cure and is not improved by addition of an injectable second-line agent. Access to rapid
DST and treatment adherence need to be strengthened to increase favorable results.
Introduction
Tuberculosis (TB) remains a significant health issue worldwide. Resistance to anti-TB drugs
makes treatment difficult. Isoniazid (H) resistance without concomitant rifampicin resistance
is a common problem. Inadequate management of isoniazid-resistant TB (Hr-TB) creates the
ideal circumstances for amplification of resistance to multidrug resistance (MDR, resistance to
at least isoniazid and rifampicin) which is much harder to treat. Detection of isoniazid resis-
tance is often delayed or overlooked entirely, and even once identified there is very limited evi-
dence to direct treatment regimen choice in such cases.
Worldwide, Hr-TB without MDR-TB is estimated at 9.5% of all cases; for new cases it is
8.1% and for previously treated cases it is 14% [1]. According to the National Surveillance
Study in Peru (2005–2006), Hr-TB without MDR-TB rate in new cases is 6.3% and with previ-
ous treatment it is 6.7% [2].
Timely detection of this and other types of resistance is important; the World Health Orga-
nization (WHO) approved the End-TB Strategy in May 2014 one of the mainstays of which is
the universal use of rapid drug susceptibility testing (DST) for early resistance detection [3]. In
Peru these measures were adopted earlier; in 2002 drug susceptibility testing for first-line and
second-line anti-TB drugs using the proportion method on Middlebrook 7H10 agar (APP)
was implemented; by 2006 implementation and decentralization of nitrate reductase assay was
initiated [4]; by 2008 MODS was validated [5]; and by 2010 the GenoType MTBDRplus
method was validated by the National Institute of Health (Instituto Nacional de Salud, INS)
[6]. This development of rapid drug susceptibility testing (DST) allowed for universal access
since 2011, which in turn facilitated early resistance detection not only for rifampicin but also
for isoniazid [7].
There is no international consensus for the treatment of Hr-TB, due to a lack of evidence;
remarkably, however, most of the emphasis is on regimens that only include first-line drugs.
The British Thoracic Society (BTS) recommended in 1998 2 months of streptomycin (S),
rifampicin (R), pyrazinamide (Z), and ethambutol (E) followed by 7 months of rifampicin and
ethambutol (2SRZE/7RE) when H resistance is diagnosed before treatment initiation, and
2RZE/10RE if the patient had already started treatment [8], a position maintained in the rec-
ommendations from the 2016 NICE clinical guidelines [9]. In 2003 the ATS (American
Isoniazid-monoresistant TB in Peru
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Thoracic Society), IDSA (Infectious Diseases Society of America), and CDC (Center of Disease
Control and Prevention), recommended HREZ and then RZE after H-resistance identifica-
tion, for a total of 6 months [10].
In the 2008 Management Guidelines, the World Health Organization (WHO) recom-
mended R,Z,E for 6–9 months, with addition of levofloxacin (Lfx) for extensive disease [11];
however, the 2010 Guidelines state that the most effective regimen for this type of resistance is
not known, and recommend that for cases which had already started treatment and have
known or suspected H resistance, HRE be maintained for 5–7 months, whilst acknowledging
that the level of evidence supporting this or any other recommendation is insufficient [12]. In
the 2014 Management Guidelines, the WHO again recommended R,Z,E for 6–9 months with
caution, both if resistance to E and Z is not known, due to risk of multidrug resistance, and in
case of resistance to H alone, due to potential for R resistance amplification; based on expert
opinions, Lfx may be added as well [13]. In the latest 2016 Management Guidelines, the WHO
makes no recommendations about Hr-TB management, due to lack of evidence [14]; new spe-
cific recommendations are expected in 2018.
In Peru, the 2006 Technical Standard for Tuberculosis Control recommended 2 months of
SHREZ for H resistance alone, followed by 1 month of HREZ, and then 5 months of HRE
twice a week (2SHRZE/1HRZE/5H2R2E2), and in case of H and S resistance, kanamycin (Km)
was to be added to the regimen 2KmRZE/1Km3RZE/6RZE [15]. The 2010 Peru Technical
Standard indicated RZE or RZE plus ciprofloxacin (Cpx) for 9 months, depending on the tim-
ing of diagnosis [16]; that same year, based on the 2008 WHO Management Guidelines, Cpx
was replaced by Lfx in all treatment regimens [11]. The treatment regimen in the 2013 Techni-
cal Standard was two months of Lfx, R, E, Z for the intensive phase, followed by seven months
of Lfx, R, E (2LfxRZE/7LfxRE)[17], which was progressively implemented. This regimen was
designed based on review and analysis of susceptibility results from 12,311 M. tuberculosis iso-
lates obtained from 2007 to 2009, in which 98.9% of H resistant non-MDR strains diagnosed
by rapid DST were found to be susceptible to at least 3 agents of a CpxRZE regimen [18]. Prior
to this 2013 recommendation, in some cases an aminoglycoside was added to the regimen, at
the discretion of the treating clinician but with no clear justification recorded.
Unlike treatment for susceptible and MDR TB, there are few studies and no clinical trials
which assess different regimens for Hr-TB without MDR-TB, and the recent review by Gegia
[19] shows that first-line treatment only is inadequate; here we report treatment outcomes for
a cohort of patients with Hr-TB treated under programmatic conditions in Peru with a stan-
dardized nine month quinolone containing regimen.
Methods
Study design and location
This is an operational, retrospective and descriptive study of a cohort of patients who received
treatment for H-resistant TB without MDR-TB in Peru from January 2012 to December 2014.
In Peru, as stated in the 2013 Technical Standard [16], all diagnosed TB cases require a sam-
ple for rapid DST and culture. If the rapid DST shows isoniazid and/or rifampicin resistance,
the APP DST is performed at the national mycobacteria reference laboratory at the INS for H,
R, E, S, Km, PAS, Lfx, capreomycin (Cm), ethionamide (Eto), and cycloserine (Cs); in Novem-
ber 2014, Cpx susceptibility testing was replaced by Lfx. Additionally, susceptibility to Z is
assessed using Wayne or MGIT assays; the national mycobacteria reference laboratory partici-
pates in the external quality assurance programme overseen by the supranational laboratory.
All cases with identified drug resistance are evaluated by Regional Retreatment Assessment
Committees to approve treatment initiation. Those cases for which treatment was started
Isoniazid-monoresistant TB in Peru
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based upon rapid DST results are subsequently reassessed using APP in order to ratify or
change the regimen based on the complete susceptibility profile.
Study subjects
All approved cases are reported and entered with a code to the National Resistant Tuberculosis
Registry (Registro Nacional de Tuberculosis Resistente, RNTR); healthcare facilities where
patients will receive treatment are required to report treatment initiation and termination, and
must perform monthly microbiological surveillance control with sputum smear microscopy
and culture. Bacteriology and DST are registered in the RNTR. Cultures and DST are also reg-
istered in NETLAB, the INS Laboratory Information System.
The cohort for evaluation included cases that fulfilled the following criteria:
• H resistance as determined by rapid DST (nitrate reductase, MODS, or Genotype
MTBDRplus) or by the APP DST. If APP DST was available, H resistance should be con-
firmed, with no Cpx or Lfx, R, Z, and E resistance identified
• Treatment initiation and termination information available (although, for the purposes of
assessing the representativeness of the evaluated cohort, data from cases with no treatment
completion dates were also collected to compare “not evaluated” cases with the evaluation
cohort)
• received Lfx, R, Z, E with or without an injectable drug (S, Km, or Cm)
The following cases registered in the RNTR were excluded:
• the APP DST demonstrated susceptibility to isoniazid
• the APP DST demonstrated MDR/XDR-TB
• patient initiated treatment for MDR-TB
• patient initiated treatment with second-line drugs due to adverse reactions to first-line
drugs, a comorbidity or medical judgement without having isoniazid resistance
Variables
The information for this study comes from the RNTR. The code for each case was entered and
the following variables were obtained: gender, age, treatment initiation and termination dates,
location of treatment administration, HIV and diabetes status, injectable drug use, rapid DST,
APP DST and available culture results. For cases lacking complete information on cultures
and susceptibility testing in RNTR, additional data was obtained from NetLab.
Each case was assigned a treatment outcome, but there are no established definitions for
treatment outcomes using this regimen; therefore, for study purposes the 2013 WHO defini-
tions were adapted [20]:
• Cured: requires two negative cultures, one during treatment and the other at the end of
treatment.
• Treatment completed: treatment is finished with no evidence of failure but does not fulfill
microbiological criteria for “cured”.
• Loss to follow-up: treatment was discontinued for over 30 consecutive days.
• Failure: positive culture at month 5 or later, or treatment change with at least two new drugs
due to lack of conversion at the end of intensive treatment phase.
Isoniazid-monoresistant TB in Peru
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• Death: patient death for any cause during treatment.
• Treatment success: cured plus treatment completed.
• Not evaluated: a treatment outcome cannot be assigned as treatment conclusion has not
been reported to the RNTR.
Data collection and statistical analysis
The information collected was entered into an Excel Microsoft Office 2016 database. Cases
were divided between cases with treatment outcome (evaluated) and those not evaluated;
variables were compared in cases which received LfxREZ and LfxREZ plus an injectable
drug within the evaluated and not evaluated groups, and then comparisons were made
between the two groups for significant differences using Chi-squared test (X2). Then cases
were divided based on treatment outcome. A univariate and multivariate logistic regression
analysis was performed to determine whether any variable affected favorable treatment out-
come. A p-value <0.05 was considered significant. The data was analyzed using STATA14
software (Stata corp, Texas USA).
Ethical considerations
The study protocol was reviewed and approved by The Union Ethics Committee (Interna-
tional Union Against Tuberculosis and Lung Disease) and the Hospital Nacional Arzobispo
Loayza (Lima, Peru) Institutional Research Ethics Committee.
Results
In the RNTR, 1973 cases of H-resistant TB without MDR-TB were identified. A total of 623
cases were excluded; 1350 started treatment with LfxREZ (n = 1143) or LfxREZ plus an
injectable drug (n = 207); of these, 403 cases had no treatment conclusion date, so treatment
outcome could not be evaluated; these cases were designated as not evaluated. There were 947
cases with treatment initiation and termination dates (791 and 156 with and without use of
injectable drug, respectively) where treatment outcome was evaluated (evaluated cases) (Fig 1).
Evaluation cohort vs. not evaluated cases
To determine whether the evaluation cohort is representative of patients treated for Hr-TB,
the characteristics of evaluated and not evaluated groups were compared. Table 1 shows these
results; there were no significant differences in gender, comorbidities (HIV, diabetes), or avail-
ability of results from rapid DST and APP DST. Patients without a treatment outcome date,
and thus not evaluated, were more likely to have been treated outside of Lima-Callao
(p = 0.02) and have started treatment in 2013/14 (p<0.05). The 15–34 age group was also
slightly over-represented amongst the non-evaluated (p = 0.03).
Characteristics of evaluated cohort (Table 1)
In the evaluated group, the most common resistance pattern was HS (33.3%), followed by H
resistance (30.1%), HSEto resistance (11.5%) and HEto resistance (6.7%); this profile did not
differ significantly from that of the group without outcome evaluation. Additional use of a sec-
ond-line injectable anti-TB drug was significantly more frequent in in 2012 and 2013 (31%
and 37% of cases) than in 2014 (1.5%), and usage was more common in Lima-Callao than in
the provinces (p<0.05 for both, S1 Table).
Isoniazid-monoresistant TB in Peru
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Treatment outcomes
Table 2 shows treatment outcomes and distribution based on study variables. Treatment suc-
cess, a composite of cure and treatment completion, was recorded for 77.2% of cases. Although
the percentages of patients experiencing failure (1.3%) and death (1.9%) were very low, the
loss to follow-up was high (19.6%), with no significant variation over the years. Therefore, the
unsuccessful treatment outcome in 22.8% was driven by loss to follow-up.
Women experienced greater treatment success than men (85.1% vs. 73.6%), with a large
gender differential in dropout and failure rates for men vs. women (22.7% vs. 12.9% and 1.7%
vs. 0.3%, respectively), with similar death rates (2.0% in men and 1.7% in women). Loss to fol-
low-up was twice as frequent amongst patients with HIV co-infection (39.0 vs. 18.4% amongst
HIV-uninfected).
Amongst patients for whom H resistance was only diagnosed with the conventional agar
proportion method–those without an available rapid H DST–the percentage of loss to follow-
Fig 1. Flowchart for case inclusion.
https://doi.org/10.1371/journal.pone.0206658.g001
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up (23.9% vs. 18.7%), failure (1.9% vs. 1.1%) and death (3.1% vs. 1.6%) was higher than for
patients with available rapid DST results. Use of a second-line injectable (vs. non-use) was
associated with a higher percentage of loss to follow-up (25.6% vs. 18.5%) and death (7.1% vs.
0.8); among treatment failure cases there were no patients who received second-line injectable
treatment. Fig 2 shows treatment outcomes by year of treatment initiation. Treatment success
was recorded for 80.1% in 2012, 75.2% in 2013, and 76.1% in 2014.
The univariate logistic regression analysis (Table 3) showed decreased treatment success to
be associated with male gender, lack of an available rapid DST for H resistance and use of a
second-line injectable drug. In the multivariate logistic regression analysis, in addition to the
previous variables, treatment initiation in 2014 was also independently associated with a less
favorable treatment outcome.
Table 1. Characteristics of evaluated and not evaluated groups.
Evaluated cases
n = 947
Not evaluated cases
n = 403
p
n % n %
Gender F 295 31.1% 126 31.3% 1.0
M 652 68.9% 277 68.7%
Age 0–14 22 2.3% 8 2.0% 0.03
15–34 603 63.7% 291 72.2%
35–54 210 22.2% 67 16.6%
>55 112 11.8% 37 9.2%
Year 2012 316 33.4% 80 19.8% <0.05
2013 283 29.9% 143 35.5%
2014 348 36.7% 180 44.7%
HIV positive 41 4.3% 11 2.7% 0.3
negative 806 85.1% 344 85.4%
Not evaluated 100 10.6% 48 11.9%
Diabetes Yes 69 7.3% 33 8.2% 0.6
No 878 92.7% 370 91.8%
Injectable TB drug Yes 156 16.5% 51 12.7% 0.08
No 791 83.5% 352 87.3%
Location Lima-Callao 614 64.8% 233 57.8% 0.02
Provinces 333 35.2% 170 42.2%
Rapid DST H resistance 760 80.2% 331 82.1% 0.2
Not available 159 16.8% 60 14.9%
Susceptible 27 2.8% 9 2.2%
MDR-TB 1 0.2% 3 0.8%
APP DST H-resistant 285 30.1% 120 29.8% 0.4
HS-resistant 316 33.7% 114 28.3%
HSEto-resistant 109 11.5% 54 13.4%
HEto-resistant 64 6.8% 29 7.2%
Other 24 2.5% 8 2.0%
Not available 149 15.4% 76 19.3%
https://doi.org/10.1371/journal.pone.0206658.t001
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Table 2. Characteristics of evaluated cases (n = 947) based on treatment outcomes.
Cured Completed treatment Loss to follow-up Failure Death Total
All 326
(34.4%)
405
(42.8%)
186
(19.6%)
12
(1.3%)
18
(1.9%)
947
100%
Sex
F 108
36.6%
143
48.5%
38
12.9%
1
0.3%
5
1.7%
295 (31.1%)
M 218
33.4%
262
40.2%
148
22.7%
11
1.7%
13
2%
652 (68.9%)
Age (years)
0–14 7
31.8%
12
54.5%
2
9.1%
0 1
4.6%
22 (2.3%)
15–34 210
34.8%
248
41.1%
130
21.6%
8
1.3%
7
1.2%
603 (63.7%)
35–54 70
33.3%
93
44.3%
37
17.7%
3
1.4%
7
3.3%
210 (22.2%)
>55 39
34.8%
52
46.4%
17
15.2%
1
0.9%
3
2.7%
112 (11.8%)
Year
2012 91
28.8%
162
51.3%
55
17.4%
1
0.3%
7
2.2%
316 (33.7%)
2013 109
38.5%
104
36.7%
60
21.2%
1
0.4
9
3.2%
283 (29.9%)
2014 126
36.2%
139
39.9%
71
20.4%
10
2.9%
2
0.6
348 (36.4%)
HIV
Positive 11
26.8%
10
24.5%
16
39.0%
1
2.4%
3
7.3%
41 (4.3%)
Negative 286
35.5%
351
43.5%
148
18.4%
9
1.1%
12
1.5%
806 (85.1%)
Not evaluated 29
29.0%
44
44.0%
22
22.0%
2
2.0%
3
3.0%
100 (10.6%)
Diabetes
Yes 18
26.1%
34
49.3%
13
18.9%
3
4.3%
1
1.4%
69 (7.3%)
No 308
35.1%
371
42.2%
173
19.7%
9
1.1%
17
1.9%
878 (92.7%)
Location
Lima 243
39.6%
219
35.7%
132
21.5%
7
1.1%
13
2.1%
614 (64.8%)
Provinces 83
24.9%
186
55.9%
54
16.2%
5
1.5%
5
1.5%
333 (35.2%)
Rapid DST
H resistance 277
36.4%
321
42.2%
142
18.7%
8
1.1%
12
1.6%
760 (80.2%)
No rapid DST
Available
42
26.4%
71
44.7%
38
23.9%
3
1.9%
5
3.1%
159 (16.8%)
Susceptible 6
22.2%
13
48.2%
6
22.2%
1
3.7%
1
3.7%
27 (2.9%)
MDR-TB 1 1 (0.1%)
APP DST
H resistance 84
29.5%
125
43.9%
67
23.5%
3
1.0%
6
2.1%
285 (30.1%)
(Continued)
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Table 2. (Continued)
Cured Completed treatment Loss to follow-up Failure Death Total
HS-resistant 100
31.6%
150
47.5%
58
18.3%
4
1.3%
4
1.3%
316 (33.4%)
HSEto-resistant 54
49.6%
36
33.0%
14
12.8%
2
1.8%
3
2.8%
109 (11.5%)
HEto-resistant 26
40.6%
18
28.1%
19
29.7%
1
1.6%
0 64 (6.8%)
Other 5
20.8%
17
70.8
1
4.2%
0 1
4.2%
24 (2.5%)
Not available 57
38.3%
59
39.6%
27
18.1%
2
1.3%
4
2.7%
149 (15.7%)
Injectable
Yes 54
34.6%
51
32.7%
40
25.6%
0 11
7.1%
156 (16.5%)
No 272
34.4%
354
44.8%
146
18.5%
12
1.5%
7
0.8%
791 (83.5%)
https://doi.org/10.1371/journal.pone.0206658.t002
Fig 2. Treatment outcome based on treatment initiation year.
https://doi.org/10.1371/journal.pone.0206658.g002
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Discussion
This study has demonstrated that the LfxREZ regimen indicated for Hr-TB in Peru results in a
favorable outcome in 77.2% of treated patients, with the dominant reason for lack of treatment
success due to a high proportion of loss to follow-up. Loss to follow-up has been a pro-
gramme-wide problem in Peru`, not specific to Hr-TB; between 2008–2010 the loss to follow
Table 3. Univariate and multivariate logistic regression analysis of variables that may affect treatment success.
Univariate analysis
OR (95% CI)
p Multivariate analysis
OR (95% CI)
p
Sex
Female Reference
Male 0.48 (0.33–070) < 0.05 0.50 (0.34–0.72) < 0.05
Age (years)
0–14 Reference
15–34
35–54
>55 1.00 (0.99–1.01) 0.7
Year
2012 Reference
2013
2014 0.89 (0.74–1.07) 0.2 0.77 (0.62–0.94) 0.01
HIV
Yes Reference
No
Not evaluated 0.97 (0.92–1.03) 0.4
Diabetes
Yes Reference
No 1.01 (0.95–1.07) 0.7
Treatment location
Lima-Callao Reference
Provinces 0.72 (0.52–1.01) 0.05
Rapid DST
H-resistant Reference
Not available
Susceptible
MDR-TB 0.74 (0.55–0.99) 0.05 0.67 (0.50–0.91) 0.01
APP DST
H-resistant Reference
HS-resistant
HSEto-resistant
HEto-resistant
Another resistance
No APP available 1.01 (0.96–1.06) 0.5
Injectable use
No
Yes 0.54 (0.37–0.79) 0.001 0.46 (0.31–0.70) < 0.05
Variables with p�0.2 on univariate analysis were included in the multivariate model; for clarity, only those variables found to be statistically significantly associated with
treatment outcome are shown in the table.
https://doi.org/10.1371/journal.pone.0206658.t003
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up was 10% for drug-susceptible TB and 18–20% for MDR TB [7]. Variables that diminished
treatment success were male gender, lack of available rapid DST for H resistance, use of
adjunctive second-line injectable drug therapy and treatment initiation in 2014.
A strength of this operational research study is the usage of nationwide programmatic data
from the National Resistant Tuberculosis Registry and inclusion of all cases approved for treat-
ment initiation for isoniazid-resistant TB. In addition, the strict microbiological inclusion cri-
terion depended upon proven isoniazid resistance at the national mycobacteria reference
laboratory, which is overseen for EQA by the supranational reference laboratory.
The registry includes a significant section (403/1350, 30%) of patients for whom no treat-
ment outcomes (“not evaluated”) had been recorded. To assure that exclusion of these patients
from the evaluation cohort would not generate a major bias, their characteristics were analyzed
and found to show no important differences regarding demographic data and disease charac-
teristics. It has only been shown that compared with evaluated patients, “not evaluated” status
was more common in the provinces than in Lima and were more frequent in 2013 and 2014
than in 2012. In the evaluation cohort, loss to follow-up was more common in the two more
recent years of study. Despite the apparent demographic and clinical similarity of the “not
evaluated” group to the “evaluated” group, there remains a significant concern that the evalu-
ated group may not accurately represent the entire cohort of LfxREZ treated patients. From
our available data we are unable to exclude the possibility that deaths, treatment failures and
loss to follow-up may have been much greater in the “not evaluated” group, which remains an
important limitation of this analysis.
Treatment success broadly consisted of half cured and half patients who had completed
treatment. Although failures and deaths were very few, the high proportion of loss to follow-
up is striking, and it is important to acknowledge the possibility that there may have been
more patients who failed treatment or died amongst this group that were not captured or rec-
ognized by the TB programme.
Men had less favourable outcomes and more loss to follow up than women, as is seen for
TB in general, regardless of drug-susceptibility. In Peru, TB mainly affects men and the age
group 15–44, and 95% of cases are seen in the lower socioeconomic strata, where men are the
ones who mainly work; this may in turn affect treatment adherence and lead to subsequent
unfavorable outcomes, since work or school are important reasons for non-adherence [21].
Lack of an available rapid DST for H resistance, and thus reliance only on the APP DST
result with longer turnaround times, may delay initiation of an adequate treatment and thus
explain lower favorable outcomes. Current implementation in Peru of universal rapid DST,
which includes isoniazid susceptibility testing–MODS and Genotype MTBDRplus–has been a
key policy for treatment success, with a standardized regimen initiated without delay (Obre-
gon Boltan G. et al. Introduction of rapid drug susceptibility tests and treatment outcomes for
multidrug-resistant TB in Peru, 2010–2015. In Press Int J Tuberc Lung Dis 2018). A drawback
to the Xpert MTB/RIF test, implemented at large-scale in several countries, although not yet in
Peru, is the lack of information about isoniazid resistance. Without these rapid DSTs, patients
included in this analysis could not have been identified; most patients would have started
2RHZE4RH, which in a recent systematic review [19] was associated with failure in 11% and
relapse in 10% of cases, and with additional acquired resistance to rifampicin (acquired
MDR-TB) in 8% of cases. It may be inferred that this source of MDR-TB has been shut off
with the implementation of rapid DST in Peru.
In 16% of cases, a second-line injectable drug was added to the standardized regimen
(LfxREZ). Among the 18 deceased patients, 61% received an injectable drug, which suggests
that the use may have been indicated for cases with a greater clinical deterioration (as this was
not algorithm-based but based on medical decision).
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Treatment initiation year was identified as a variable that decreased favorable outcome in
2014 more than in 2013 and 2012; the multivariate analysis shows that this effect persists
regardless of injectable drug use and additional resistance profiles. For the most part, the effect
is due to increased loss to follow-up; this is a significant gap that the programme must urgently
address.
In common with any other operational research study which takes advantage of available
programmatic data, there are certain limitations to take into consideration. This is a single-
cohort study, with no control group.
In order to be able to define treatment outcome, treatment initiation and termination dates
are needed; healthcare facilities are required to report these dates, and if this is not performed
adequately, not all cases can be evaluated. This situation was more common in the provinces
than in Lima-Callao. Thirty percent of patients were excluded as “not evaluated”; however, no
significant differences that compromise generalizability were seen between the groups, and
therefore the study is considered representative of Peru. The National Resistant Tuberculosis
Registry includes no treatment information prior to diagnosis of drug-resistance. As treatment
cards are not available, there is no opportunity for source data verification.
In Peru, cases treated for drug-resistance are required to have monthly cultures throughout
the course of treatment [16], however this is not performed in all cases, particularly when
cough has resolved or become non-productive, which limits the determination of “cured” sta-
tus. There are no defined criteria for treatment outcome with this type of resistance, in particu-
lar for cure and failure; therefore WHO criteria were adapted for this study [20]. Given the
high loss to follow-up the true failure rate is difficult to assess. An additional limitation of this
analysis is that the information system does not record data on acquired resistance or post-
treatment relapse.
The presence of H resistance is associated with unfavorable treatment outcomes. In a pro-
spective observational study conducted in Lima, Peru, on 1039 cases between 2010 and 2011,
8% of cases had H resistance alone. These cases had a higher risk of failure (2%) and death
(5%) than susceptible cases [22].
In other retrospective studies in which treatment regimens were assessed, treatment out-
comes are highly variable. Menzies et al performed a meta-analysis based on studies conducted
between 1965 and 2008, with very variable regimens, and highoighted the complete lack of
randomized controlled clinical trials. In cohorts that used 2HREZS/1HREZ/5HRE with a con-
tinuation phase of daily, or 2 or 3 times a week administration, the failure rates were 18–44%.
Other regimens which included R use only in the initial phase had a relapse and failure rate of
up to 70%. Unfavorable outcomes were found to be related to use of R exclusively during the
initial phase, and it is recommended that at least 4 effective drugs be used during the intensive
phase and 3 during the continuation phase [23].
Gegia et al expanded the meta-analysis mentioned above with studies conducted up to
March 2015; the use of first-line drugs to treat H resistance was evaluated. Cases which used
the WHO recommended regimen for new patients (2HREZ/4HR) showed an 11% failure rate,
a 10% relapse rate, and development of MDR-TB in 8%. Among those who received the WHO
regimen recommended for previously treated patients (2HREZS/1HREZ/5HRE), failure rate
was 6%, relapse rate was 5%, and 3% developed MDR-TB. Therefore, the development of bet-
ter regimens is recommended [19].
There is a distinct paucity of data on the use of fluoroquinolones for treatment of Hr-TB
though there are some encouraging early signals. In an evaluation of 40 patients conducted in
Denmark from 2002 to 2007 with H resistance determined by BACTEC 460, the REZ regimen
plus fluoroquinolone for an average of 277 days had a favorable outcome in 90% of cases [24].
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Further evidence for the use of fluoroquinolones instead of isoniazid comes from three
large clinical trials using a fluoroquinolone (moxifloxacin or gatifloxacin) with the aim of
reducing treatment for drug-susceptible TB to 4 months [25–27]. Treatment outcomes
achieved by fluoroquinolone regimens were non-inferior compared with those seen with con-
ventional treatment (2RHZE4RH).
Lee et al presented treatment outcomes with fluoroquinolone use (Lfx and Mfx) in 75 cases
of H resistance as determined by DST using proportion method. This regimen had R (94.7%),
E (90.7%), Z (82.7%), and S (2.7%) with a favorable treatment outcome in 97.3% and only
1.3% failures [28].
Overall the use of fluoroquinolones improves treatment outcomes over non-fluoroquino-
lone containing regimens, but studies are scarce. Current evidence suggests that regimens for
H resistant TB should at least include R throughout treatment, should include at least 4 effec-
tive drugs for the induction phase and should probably last over 6 months, perhaps with addi-
tional benefit from prolonging to 9 months. A forthcoming systematic review, undertaken to
inform new WHO guidance on Hr-TB management, should shed further light on the mini-
mum requirements for an effective regimen.
The present study evaluated a much greater number of cases (n = 947) than previously
reported; favorable outcome was significantly affected by loss to follow-up, which was greater
than in other studies, but failure was minimal (1.2%).
In case of no resistance to the drugs included in the treatment, the regimen indicated in
Peru for treatment of isoniazid resistant TB has a high treatment success rate and does not
require the addition of an injectable drug to the regimen. In programmatic conditions, with
the use of rapid DST which includes an isoniazid susceptibility test, the regimen 2LfxRZE/
7LfxRE has shown strong performance in patients who remained in the programme. The regi-
men was derived from a detailed prior analysis of national drug-resistance epidemiology in
strains resistant to isoniazid but susceptible to rifampicin. Improved adherence and sustained
access to rapid DST may serve to further improve treatment success. In places where the resis-
tance profile is known in strains resistant to isoniazid but not to rifampicin, the use of rapid
DST with a rapid isoniazid test is recommended, along with the use of the 2LfxRZE/7LfxRE
regimen, with particular attention to minimize loss to follow-up during treatment.
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